Results of Scheme Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2024
0mins
Should l Buy ?
Source: Newsfilter
Bionomics Shareholder Approval: Bionomics Limited has received approval from 96% of its shareholders for a proposed re-domiciliation to the United States, where Neuphoria Therapeutics Inc. will become the parent company.
Next Steps and Conditions: The implementation of the Scheme is subject to several conditions, including court approval in Australia, with an expected completion date around December 24, 2024, when shares of Neuphoria are anticipated to begin trading on Nasdaq.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
